COCP — Cocrystal Pharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1412486 ·
Last close
$1.17
Market Cap
$22.54M
52W High
$2.03
52W Low
$0.76
ADV30
55,177
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 105,000 | — | -3,184,000 | -3,164,000 | 4,649,000 | 2,169,000 | 3,605,000 |
| Mar 2026 | 225,000 | — | -2,356,000 | -2,299,000 | 7,426,000 | 4,685,000 | 3,310,000 |
| Dec 2025 | 0 | — | -2,481,000 | -2,426,000 | 9,712,000 | 7,025,000 | 3,381,000 |
| Sep 2025 | 0 | — | -2,089,000 | -2,049,000 | 10,446,000 | 7,729,000 | 2,777,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-7,593,000
Investing CF
$-12,000
Financing CF
$1,032,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.79
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-344,548,000
Inventory
—
Receivables
$761,000
ST Investments
—
EBIT TTM
$-9,034,000
Pretax Income TTM
$-8,829,000
Interest Exp TTM
—
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$330,000
EBITDA
$-10,060,000
Free Cash Flow
$-4,318,750
Enterprise Value
$23,058,368
Total Cash
$2,169,000
Total Debt
$1,341,000
Shares Out
19,263,200
Trailing EPS
$-0.75
Book Value
$0.08
ROE
-311.7%
ROA
-96.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -9,019,000 | -8,831,000 | 9,712,000 | 3,381,000 | 6,331,000 | -8,192,000 |
| Dec 2024 | 0 | -17,878,000 | -17,504,000 | 13,456,000 | 3,933,000 | 9,523,000 | -16,485,000 |
| Dec 2023 | 0 | -21,159,000 | -17,984,000 | 31,259,000 | 4,875,000 | 26,384,000 | -14,666,000 |
| Dec 2022 | 0 | -18,137,000 | -38,837,000 | 40,840,000 | 1,273,000 | 39,567,000 | -21,435,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.58
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PVCT | PROVECTUS BIOPHARMACEUTICALS, INC. | $23.12M | $0.05 | — |
| NXTC | NextCure, Inc. | $23.25M | $5.08 | — |
| TXMD | TherapeuticsMD, Inc. | $23.73M | $2.05 | — |
| UPC | Universe Pharmaceuticals INC | $23.79M | $4.75 | — |
| RADX | Radiopharm Theranostics Ltd | $23.86M | $1.65 | — |
News headlines (Yahoo Finance, 1h cache)
Cocrystal Pharma’s new CEO hopes to crack the norovirus code
2026-09-15 12:56 · Yahoo
Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment
2026-09-09 11:00 · Yahoo
Cocrystal Pharma: The Strategic Reset Investors May Be Missing
2026-08-31 15:39 · Yahoo
COCP: $5 Million Private Placement with OPKO Health
2026-08-20 11:20 · Yahoo
Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors
2026-08-17 15:17 · Yahoo
Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health
2026-08-03 11:00 · Yahoo
Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer
2026-06-03 11:00 · Yahoo
COCP: Presentation Highlights CDI-988
2026-06-01 11:35 · Yahoo
Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results
2026-05-15 12:00 · Yahoo
Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection
2026-04-30 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.